Compare AU

Compare JNDQ vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Nasdaq Next Gen 100 ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Nasdaq Next Gen 100 ETF (JNDQ) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

JNDQ

CURE

Popularity

Low

Low

Pearlers invested

24

82

Median incremental investment

$731.64

$619.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,130.30

$1,325.00

Average age group

> 35

> 35


Key Summary

JNDQ

CURE

Strategy

JNDQ.AX was created on 2024-02-20 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. JNDQ.AX aims to track the performance of the Nasdaq Next Generation 100 Index (before fees and expenses).

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

SUPER MICRO COMPUTER INC (3.33 %)

MONOLITHIC POWER SYSTEMS INC (2.81 %)

ALNYLAM PHARMACEUTICALS INC (2.04 %)

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

Top 3 industries

Information Technology (35.37 %)

Health Care (18.40 %)

Consumer Discretionary (13.53 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.48 %

0.45 %


Key Summary

JNDQ

CURE

Issuer

BetaShares

Global X

Tracking index

Nasdaq Next Generation 100 Index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.48 %

0.45 %

Price

$17.80

$50.00

Size

N/A

$38.656 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

0.05 %

4.24 %

Market

ASX

ASX

First listed date

21/02/2024

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

JNDQ

CURE

Popularity

Low

Low

Pearlers invested

24

82

Median incremental investment

$731.64

$619.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,130.30

$1,325.00

Average age group

> 35

> 35


Pros and Cons

JNDQ

CURE

Pros

  • Higher price growth

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

  • Lower price growth

JNDQ

CURE

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield

Home